Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
J Neuroimmunol
; 389: 578328, 2024 04 15.
Article
en En
| MEDLINE
| ID: mdl-38471284
ABSTRACT
Multiple sclerosis (MS) exhibits poor immune regulation and subnormal interferon (IFN-ß) signaling. Secondary Progressive MS displays waning exacerbations, relentless neurodegeneration, and diminished benefit of therapy. We find dysregulated serum protein balance (Th1/Th2) and excessive gene expression in Relapsing-Remitting MS vs. healthy controls (8700 differentially-expressed genes, DEG) and intermediate levels in SPMS (3900 DEG). Olfactory receptor genes (chemosensing), and WNT/ß-catenin (anti-inflammatory, repair) and metallothionein (anti-oxidant) gene pathways, have less expression in SPMS than RRMS. IFN-ß treatment decreased pro-inflammatory and increased metallothionein gene expression in SPMS. These gene expression biomarkers suggest new targets for immune regulation and brain repair in this neurodegenerative disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Neurodegenerativas
/
Esclerosis Múltiple Crónica Progresiva
/
Esclerosis Múltiple Recurrente-Remitente
/
Esclerosis Múltiple
Límite:
Humans
Idioma:
En
Revista:
J Neuroimmunol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos